Itraconazole therapy for infant hemangioma: Two case reports

Area of Science:

• Pediatric Dermatology
• Oncology

Background:

• Infantile hemangiomas (IHs) are common pediatric tumors requiring intervention for cosmetic and functional reasons.
• Current first-line treatments include beta-blockers and corticosteroids.
• Itraconazole, an antifungal, has emerged as a potential alternative therapy.

Observation:

• Two cases of infantile hemangiomas were treated with itraconazole.
• The therapeutic course spanned 80-90 days.
• Significant lesion reduction and good patient/parent compliance were observed.

Findings:

• Itraconazole treatment resulted in over 90% visible lesion fading.
• No significant adverse side effects were reported during the treatment period.
• The antifungal medicine demonstrated a favorable safety and efficacy profile in these IH cases.

Implications:

• These findings support itraconazole as a viable therapeutic option for infantile hemangiomas.
• Larger clinical trials are necessary to validate these results.
• Further basic and clinical studies are warranted to optimize itraconazole treatment protocols for IHs.